secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001490978-23-000089
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q2 revenue $35.2M (-8.5% YoY); raises software revenue guidance, cuts drug discovery outlook
--------------------------------------------------------------------------------

- Net income $4.3M vs net loss $47.7M YoY, driven by $45.0M other income and $20.4M tax benefit.
- Non-GAAP net loss $56.8M vs $43.8M YoY; operating expenses rose 23.7% to $74.9M.
- Software revenue growth guidance raised to 15%-18%; drug discovery revenue guidance cut to $50M-$70M from $70M-$90M.
- IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial for AML/MDS expected in 2023.
- Zai Lab elected not to continue discovery collaboration; program returned to wholly-owned by Schrödinger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/0001490978-23-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/sdgr-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001490978-23-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer